Financial Data and Key Metrics Changes - Total revenues for 2025 were EUR 2.9 billion, a slight increase from the prior year despite a decrease in COVID-19 vaccine revenues [27] - The company ended 2025 with EUR 17.2 billion in cash equivalents and security investments, positioning it strongly for future investments [28] - Adjusted non-IFRS net loss for 2025 was EUR 117 million [29] Business Line Data and Key Metrics Changes - The company maintained over 50% market share in major markets for its COVID vaccine, distributed in over 180 countries [6] - R&D expenses were approximately EUR 2.1 billion, slightly decreased from the prior year, aided by cost savings from active portfolio management [27] - The oncology programs advanced significantly, with over 4,000 patients enrolled across phase 2 and phase 3 studies [6][8] Market Data and Key Metrics Changes - The company anticipates lower COVID-19 vaccine revenues in 2026 due to declining demand in both the U.S. and European markets [30][31] - The U.S. market is expected to be particularly competitive, impacting revenue generation [30] Company Strategy and Development Direction - The company aims to transition to a tumor-centric clinical development program focused on high-incidence cancers, including lung and breast cancer [8] - A new independent company will be established to pursue next-generation mRNA innovations, with BioNTech retaining a minority stake [10][11] - The strategic focus will remain on late-stage oncology assets and combination therapies to maximize value [11][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute its strategy and achieve significant clinical data output from 2026 to 2029 [33] - The transition to a new leadership structure is planned for the end of 2026, aligning with key milestones and data readouts [49][50] Other Important Information - The company has established a partnership with BMS to strengthen its oncology programs and de-risk its pumitamig initiatives [6][8] - The company is preparing for multiple late-stage data readouts in 2026, which are expected to inform pivotal trials [8][25] Q&A Session Summary Question: How will the mRNA therapeutics be split between BioNTech and the new company? - Management confirmed that all current mRNA capabilities will remain with BioNTech, while the new company will focus on next-generation innovations [37][40] Question: What is the profile for the new CEO search? - The supervisory board is looking for leaders with strong experience in late-stage development and commercial execution [44][46] Question: Why is the leadership transition happening now? - The transition is planned for the end of 2026, coinciding with significant data readouts and the need for industrialization [49][50] Question: Will BioNTech contribute capital to the new company? - BioNTech will not contribute cash but will transfer certain rights and mRNA technologies [54][55] Question: What are the expectations for COVID-19 vaccine revenues in 2026? - Lower revenues are anticipated due to market normalization and seasonal demand [95][96]

Financial Data and Key Metrics Changes - Total revenues for 2025 were EUR 2.9 billion, a slight increase from the prior year, despite a decrease in COVID-19 vaccine revenues [27] - R&D expenses were approximately EUR 2.1 billion, a slight decrease from the prior year, enabled by cost savings and positive effects from cost-sharing with BMS [27] - The company ended 2025 with EUR 17.2 billion in cash equivalents and security investments, positioning it strongly for future investments [28] - An adjusted non-IFRS net loss of EUR 117 million was reported for 2025 [29] Business Line Data and Key Metrics Changes - The company maintained over 50% market share in the COVID vaccine market, distributing its vaccine in over 180 countries [6] - Significant progress was made in oncology programs, with over 4,000 patients enrolled across phase II and phase III studies [6] - The company executed strategic deals, including acquiring Biotheus and CureVac, to strengthen its oncology pipeline [7] Market Data and Key Metrics Changes - The company anticipates lower COVID-19 vaccine revenues in 2026 compared to 2025, driven by declines in both European and U.S. markets [30] - The U.S. market is expected to be competitive and dynamic, impacting revenue generation [30] - In Germany, direct sales of COVID-19 vaccines will significantly affect the company's top line [31] Company Strategy and Development Direction - The company aims to become a multi-product company by 2030, focusing on oncology and personalized medicine [10] - Key priorities for 2026 include accelerating late-stage development of oncology assets, building momentum in combination-based approaches, and evolving to a tumor-centric clinical development program [8] - The company plans to leverage its diverse clinical assets for combination strategies to address multiple lines of treatment [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and disciplined resource allocation, focusing on late-stage programs [8] - The transition to a new independent company for next-generation mRNA innovations is expected to enhance BioNTech's strategic focus [10] - Management anticipates a sustained cadence of event-driven late-stage readouts from 2026 to 2030, with significant potential to improve patient outcomes [9] Other Important Information - The company will supplement its IFRS reporting with adjusted non-IFRS measures to provide better context for business performance [28] - A binding agreement for the new company is expected to be signed by the end of the first half of 2026 [11] Q&A Session Summary Question: How will the mRNA therapeutics be split between BioNTech and the new company? - Management confirmed that all current mRNA capabilities will remain with BioNTech, while the new company will focus on next-generation innovations [38][40] Question: What is the profile for the new CEO search? - The supervisory board is looking for leaders with strong experience in late-stage development and commercial execution [46] Question: Why is the management transition happening now? - The transition is planned for the end of 2026, aligning with key milestones and data readouts [49][50] Question: Will BioNTech contribute capital to the new company? - BioNTech's contribution will relate to certain rights and mRNA technologies, not cash [54] Question: What are the expectations for COVID-19 vaccine revenues in 2026? - Lower revenues are anticipated due to market normalization and seasonal demand [95]

Financial Data and Key Metrics Changes - Total revenues for 2025 were EUR 2.9 billion, a slight increase from the prior year despite a decrease in COVID-19 vaccine revenues [26] - The company ended 2025 with EUR 17.2 billion in cash equivalents and securities, positioning itself strongly for future investments [27] - Adjusted non-IFRS net loss for 2025 was EUR 117 million, reflecting the impact of various expenses [28] Business Line Data and Key Metrics Changes - The company maintained over 50% market share in the COVID vaccine market, distributing its vaccine in over 180 countries [5] - Revenue from the BMS collaboration contributed EUR 613 million, offsetting declines in COVID-19 vaccine revenues [26] - R&D expenses were approximately EUR 2.1 billion, slightly decreasing from the prior year due to cost savings and collaboration benefits [26] Market Data and Key Metrics Changes - The company anticipates lower COVID-19 vaccine revenues in 2026, particularly in the U.S. and Europe, as the market normalizes [30] - The U.S. market is expected to be competitive, leading to lower revenues, while Germany's direct sales will significantly impact overall top line [30][96] Company Strategy and Development Direction - The company aims to accelerate late-stage development of oncology assets and focus on combination-based approaches [6] - A new independent company will be established to pursue next-generation mRNA innovations, allowing BioNTech to sharpen its strategic focus on its late-stage pipeline [9][10] - The company plans to transition from a platform-centric to a tumor-centric clinical development program, targeting high-incidence cancers [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and disciplined resource allocation, focusing on late-stage programs [6][27] - The company expects a sustained cadence of late-stage readouts from 2026 to 2030, with multiple pivotal trials planned [8] - Management emphasized the importance of maintaining a strong balance sheet while advancing key programs [33] Other Important Information - The company is transitioning leadership, with Ugur Sahin and Özlem Türeci remaining through the transition period [44] - The company is preparing for potential launches in oncology, including endometrial cancer, while building commercial capabilities [44] Q&A Session Summary Question: How will the mRNA therapeutics be split between BioNTech and the new company? - Management confirmed that all current mRNA capabilities will remain with BioNTech, while the new company will focus on next-generation innovations [36][39] Question: What is the profile for the new CEO? - The supervisory board is looking for leaders with strong experience in late-stage development and commercial execution [42][44] Question: Why is the leadership transition happening now? - The transition is planned for the end of 2026, aligning with key milestones and data readouts [46][47] Question: Will BioNTech contribute capital to the new company? - BioNTech will not contribute cash but will provide certain rights and mRNA technologies [51][53] Question: What are the expectations for COVID-19 vaccine revenues in 2026? - Lower revenues are anticipated due to market normalization, particularly in the U.S. and Europe [30][96]

BioNTech Conference Call Summary Company Overview - **Company**: BioNTech - **Industry**: Biotechnology, specifically focusing on mRNA technology and oncology treatments Key Points and Arguments Company Growth and Achievements - BioNTech, in partnership with Pfizer, has delivered **5 billion doses** of vaccines globally, maintaining leadership in the COVID vaccine market [2][3] - The company has pivoted back to oncology with **25 clinical trials** ongoing and **16 clinical programs** [2][3] - BioNTech's financial position is strong, ending the year with over **$17 billion** in cash and cash equivalents [3] Clinical Trials and Pipeline - BioNTech has **25 late-stage programs** running, with over **4,000 patients** enrolled in clinical trials [5] - The company expects **15 phase 3 readouts** in 2026 and 2027, indicating a robust pipeline [5][21] - Key oncology assets include: - **Prometimic**: A PD-L1 VEGF bispecific antibody showing an **85% objective response rate** in small cell lung cancer and **70% in triple-negative breast cancer** [9] - **Gutysava**: An antibody targeting regulatory T cells, showing a **54% reduction in the risk of death** compared to chemotherapy in squamous non-small cell lung cancer [12] - **B7-H3 ADC**: Targeting multiple solid tumors with a favorable safety profile [14] Strategic Partnerships and Acquisitions - BioNTech has executed strategic deals, including a partnership with BMS to strengthen execution and de-risk programs [3] - The acquisition of BioPhios and CureVac has enhanced BioNTech's position in the mRNA field [3] Future Objectives and Strategies - In 2026, BioNTech aims to: - Accelerate late-stage development of oncology assets - Engage in multiple combination strategies - Shift from a platform-centric to a tumor-centric clinical development approach [6] - The company is focusing on a **synergy-driven development strategy** across next-generation immunomodulators, targeted therapies, and mRNA cancer immunotherapies [7] Combination Therapy Approach - BioNTech is pursuing a combination therapy strategy, integrating ADCs with immunotherapies and mRNA vaccines to enhance treatment efficacy [17][18] - The company believes that combination therapies will provide durable control in patients and open clinical benefits for those not responding to checkpoint blockade [30] Financial Management and Future Plans - BioNTech plans to use its cash reserves primarily for developing its internal pipeline and may consider inorganic acquisitions or collaborations in the future [39] Additional Important Information - The company has a strong focus on high-incidence cancers such as lung cancer and breast cancer, with strategies tailored to address various lines of treatment [18] - BioNTech anticipates a steady news flow from multiple late-stage trial readouts throughout 2026, supporting rapid decision-making and value creation [21] This summary encapsulates the key points discussed during the BioNTech conference call, highlighting the company's strategic direction, clinical advancements, and financial outlook.

Financial Data and Key Metrics Changes - Total revenues for Q3 2025 were EUR 1,519 million, an increase from EUR 1,245 million in Q3 2024, primarily driven by a $700 million recognition from the BMS collaboration [34] - The net loss for Q3 2025 was EUR 29 million, compared to a net income of EUR 198 million in the same period last year, mainly due to settlement disputes [36] - Cash, cash equivalents, and security investments totaled EUR 16.7 billion at the end of Q3 2025, including a $1.5 billion upfront payment from BMS [36] Business Line Data and Key Metrics Changes - The company is focusing on two priority pan-tumor programs: pumitamig and mRNA cancer immunotherapies, with multiple ongoing phase II and III trials [39] - Significant progress was made in advancing pumitamig, with global registration trials in lung cancer and plans to initiate a TNDC phase III trial [8][9] Market Data and Key Metrics Changes - The company continues to see stable market share and pricing for its COVID-19 vaccine, COMIRNATY, with U.S. vaccination rates around 20% [81] - The updated revenue guidance for 2025 was increased to EUR 2.6 billion - EUR 2.8 billion, mainly due to the BMS collaboration [37] Company Strategy and Development Direction - The company aims to build a global immunotherapy powerhouse, focusing on a diversified clinical pipeline that includes mRNA immunotherapies and next-generation immunomodulators [5][6] - The strategy includes a three-wave plan for pumitamig, focusing on establishing foundational indications, expanding opportunities, and elevating clinical impact through novel combinations [14][15] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of generating meaningful data across oncology programs to steer late-stage decisions and maintain financial discipline [39] - The company is committed to transforming scientific advances into late-stage progress in priority oncology programs while preparing for commercialization [11] Other Important Information - The company hosted its second AI day, showcasing AI-based approaches for personalized therapy development [10] - The company plans to present additional clinical data at the upcoming annual Innovation Series R&D Day event on November 11 [39] Q&A Session Summary Question: Market opportunity for MSS-CRC and first-line gastric cancer - Management highlighted that both indications are high medical need areas, and the combination of VEGF-A and PD-L1 blocking has potential for improved clinical benefit [44][45] Question: Delay in BLA filing for BNT323 - The delay is due to ongoing discussions with the FDA regarding additional data needs, with plans to submit in 2026 [52][71] Question: Strategy for pumitamig's establishment and elevation - The three-wave strategy is designed to focus on speed to market while generating data in combination studies [56][57] Question: Phase II details for BNT327 in triple-negative breast cancer - Management confirmed that efficacy, safety, and dose data will be presented at SABCS [62] Question: Collaboration with Bristol Myers Squibb - The collaboration involves a Joint Steering Committee for decision-making on clinical development, allowing flexibility for both partners [88][89]

BioNTech's Vision and Strategy - BioNTech aims to build a global immunotherapy powerhouse translating science into survival[13] - BioNTech has distributed 5 billion doses of COVID-19 vaccine globally[12] - BioNTech is leveraging AI to pioneer personalized immunotherapies[62] InstaDeep's AI Capabilities and Technologies - InstaDeep's AI supercomputer, Kyber, has ~500 PetaFLOPS of Nvidia H100 GPUs and 86,000 CPU Cores[105] - InstaDeep's AI training platform, AIChor, has seen +15,000 experiments per month in 2025 with +75% GPU usage[109] - Nucleotide Transformer (NTv3) pre-trained on genomes from >150,000 species and post-trained on >17,000 functional tracks across 16 species[154] AI-Driven Innovation in Genomics and Proteomics - InstaNovo V2 achieves up to 2x the number of identifications in peptide sequencing[263] - AI-assisted tissue annotation tool increased pathologist efficiency fivefold (5x)[265] - AI pipeline achieves an average 50,000-fold TCR binding enhancement increase over WT[345]